Advanced search
Add to list

Curcumin-derived functionalized thiazepanes to selectively target colon cancer cells

Julie De Munck (UGent) , Charlotte Grootaert (UGent) , Nathan Vanwinsen (UGent) , Matthias D'hooghe (UGent) and John Van Camp (UGent)
Author
Organization
Project

Citation

Please use this url to cite or link to this publication:

MLA
De Munck, Julie, et al. “Curcumin-Derived Functionalized Thiazepanes to Selectively Target Colon Cancer Cells.” OncoPoint Symposium, 8th, Abstracts, 2022.
APA
De Munck, J., Grootaert, C., Vanwinsen, N., D’hooghe, M., & Van Camp, J. (2022). Curcumin-derived functionalized thiazepanes to selectively target colon cancer cells. OncoPoint Symposium, 8th, Abstracts. Presented at the 8th OncoPoint Symposium (OncoPoint 2022), Ghent, Belgium.
Chicago author-date
De Munck, Julie, Charlotte Grootaert, Nathan Vanwinsen, Matthias D’hooghe, and John Van Camp. 2022. “Curcumin-Derived Functionalized Thiazepanes to Selectively Target Colon Cancer Cells.” In OncoPoint Symposium, 8th, Abstracts.
Chicago author-date (all authors)
De Munck, Julie, Charlotte Grootaert, Nathan Vanwinsen, Matthias D’hooghe, and John Van Camp. 2022. “Curcumin-Derived Functionalized Thiazepanes to Selectively Target Colon Cancer Cells.” In OncoPoint Symposium, 8th, Abstracts.
Vancouver
1.
De Munck J, Grootaert C, Vanwinsen N, D’hooghe M, Van Camp J. Curcumin-derived functionalized thiazepanes to selectively target colon cancer cells. In: OncoPoint Symposium, 8th, Abstracts. 2022.
IEEE
[1]
J. De Munck, C. Grootaert, N. Vanwinsen, M. D’hooghe, and J. Van Camp, “Curcumin-derived functionalized thiazepanes to selectively target colon cancer cells,” in OncoPoint Symposium, 8th, Abstracts, Ghent, Belgium, 2022.
@inproceedings{01HQ2WDWASM6T34FXT5CVPQRTY,
  author       = {{De Munck, Julie and Grootaert, Charlotte and Vanwinsen, Nathan and D'hooghe, Matthias and Van Camp, John}},
  booktitle    = {{OncoPoint Symposium, 8th, Abstracts}},
  language     = {{eng}},
  location     = {{Ghent, Belgium}},
  title        = {{Curcumin-derived functionalized thiazepanes to selectively target colon cancer cells}},
  year         = {{2022}},
}